The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Patil N, Paulose RM, Udupa KS, Ramakrishna N, Ahmed T

Pulmonary Toxicity of Bleomycin - A Case Series from a Tertiary Care Center in Southern India.

Journal of clinical and diagnostic research : JCDR. 2016;10(4):FR01-3

Stein ME, Zidan J, Charas T, Gershuny A, Ben-Yosef R

Bleomycin-induced pneumonitis in three patients treated with chemotherapy for primary advanced seminoma.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2015;20(3):928-32

Ahmed BM, Al-Zakwani IS

Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2013;19(1):3-7

Rashid RS

Bleomycin lung: a case report.

BMJ case reports. 2009;2009

Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST

Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.

Annals of hematology. 2011;90(1):67-72

Godoy MC, Nonaka D, Raphael BG, Vlahos I

Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure.

Chest. 2008;134(1):207-12

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(30):7614-20

Sleijfer S

Bleomycin-induced pneumonitis.

Chest. 2001;120(2):617-24

Maher J, Daly PA

Severe bleomycin lung toxicity: reversal with high dose corticosteroids.

Thorax. 1993;48(1):92-4

White DA, Stover DE

Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.

Chest. 1984;86(5):723-8

Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP

Pulmonary complications associated with combination chemotherapy programs containing bleomycin.

The American journal of medicine. 1983;74(4):557-63

Perez-Guerra F, Harkleroad LE, Walsh RE, Costanzi JJ

Acute bleomycin lung.

The American review of respiratory disease. 1972;106(6):909-13

Giaccone G, Risio M, Bonardi G, Calciati A

Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report.

Tumori. 1986;72(3):331-3